Liana Kelly
Family · Brunswick, MENPI 1649312638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 29.1% of the total. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$1K
- AstraZeneca$661
- Abbott$452
- Tandem Diabetes Care, Inc.$353
- Boehringer Ingelheim$282
- plus $499 from 7 others
What the payments were for
- Food & beverage$4,49096%
- Education$1944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,365 |
| Dexcom, Inc. | 18 | $1,073 |
| AstraZeneca | 27 | $661 |
| Abbott | 6 | $452 |
| Tandem Diabetes Care, Inc. | 5 | $353 |
| Boehringer Ingelheim | 7 | $282 |
| Madrigal Pharmaceuticals | 2 | $218 |
| Bayer | 1 | $123 |
| BETA Bionics, Inc. | 4 | $78 |
| Insulet Corporation | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $20 |
| Medtronic | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$481
- DEXCOM G6 TRANSMITTER$397
- DEXCOM G7 GSS (161)$281
- FREESTYLE LIBRE 3$263
- Ozempic$222
- DEXCOM STELO GLUCOSE BIOSENSOR$158
- REZDIFFRA$134
- JARDIANCE$125
- Kerendia$123
- FARXIGA$123
- FreeStyle Libre$123
- t:slim X2 Insulin Pump with Control-IQ$105
How this compares
$4,684 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $334,045 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $113,549 |
| MounjaroTirzepatide | 73 | $80,637 |
| JardianceEmpagliflozin | 91 | $77,700 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $77,343 |
| Humulin R U-500Insulin Regular, Human | 15 | $42,428 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $40,617 |
| TrulicityDulaglutide | 21 | $39,431 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $36,686 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 123 | $23,557 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $22,493 |
| JanuviaSitagliptin Phosphate | 23 | $17,655 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $16,898 |
| Novolog FlexpenInsulin Aspart | 63 | $16,023 |
| NovologInsulin Aspart | 31 | $13,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Levemir | $1,365 | $350,617337 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $14 | $125,123125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $282 | $86,461102 claims |
| AstraZenecaFarxiga | $661 | $7,78812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Brunswick
- Kristen Schroeder-CyrBrunswick$5K
- Julie KarlsenBrunswick$3K
- Jana ChristmanBrunswick$2K
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Natalie BubierLewiston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.